pharmesis international ltd
(PHM:Singapore Exchange Securities Trading)

Last $0.03 SGD

Change Today 0.00 / 0.00%

Volume 0.0

PHM On Other Exchanges

Symbol

Exchange

PHM:SP

As of 11:17 PM 05/2/13 All times are local (Market data is delayed by at least 15 minutes).

pharmesis international ltd (PHM) Snapshot

Open $0.03		Previous Close $0.03
Day High $0.03		Day Low $0.03
52 Week High 01/4/13 - $0.05		52 Week Low 09/3/12 - $0.01
Market Cap 6.6M		Average Volume 10 Days 0.0
EPS TTM $-0.08		Shares Outstanding 200.0M
EX-Date --		P/E TM --
Dividend --		Dividend Yield --

Current Stock Chart for PHARMESIS INTERNATIONAL LTD (PHM)

PHM:SP Historical Stock Quote
PHM:SP Advanced Stock Chart

Related News

No related news articles were found.

pharmesis international ltd (PHM) Related Businessweek News

No Related Businessweek News Found

pharmesis international ltd (PHM) Details

Pharmesis International Ltd, an investment holding company, engages in the development, manufacture, and sale of western medicines, health tonic products, and traditional Chinese medicine (TCM) formulated products for the treatment of illnesses relating to the liver and gall bladder in the People’s Republic of China. It is also involved in the wholesale of chemical drugs, biological raw products, TCMs, antibiotics, and antibiotics agents. The company offers its western medicines and TCM formulated products in the form of tablets, granules, and pills. Its products comprise Anetholtrithione for the treatment of illness relating to the liver and gall bladder; Gansu for the treatment of acute and chronic hepatitis; AFenKa for the treatment of migrane, pain, headache, nasosinusitis, cold, muscle pain, menstrual pain, toothache, and arthritis; and LianPu ShuangQing for the treatment of acute inflammation, such as dysentery and intestinal infection. Pharmesis International also offers Xiao Shi Jian Pi tablets for the treatment of flatus, inappetency, dyspepsy, and spleen weakness; Er Ding granules for the treatment of jaundice, as well as clears heat and toxics; ShuLingHou Pian tablets, which clear heat and regenerate body fluid, as well as for the treatment of acute and chronic pharyngitis, laryngitis, sore throat, and hoarseness; Simvastatin tablets that control hypercholesterolemia and treat coronary heart diseases; and Wuling Jiao Nang granules, which disperse water accumulation, regulate water circulation, and dispel dampness. The company markets its western drugs under the Kinna brand name; and TCM formulated drugs under the Longlife brand name to approximately 2,000 hospitals through its sales and marketing personnel. Pharmesis International Ltd was founded in 1996 and is headquartered in Chengdu, the People’s Republic of China.

Detailed PHM:SP Company Description...

www.pharmesis.com

Founded in 1996

pharmesis international ltd (PHM) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

pharmesis international ltd (PHM) Key Developments

Pharmesis International Ltd. Reports Un-Audited Consolidated Earnings Results for the First Quarter Ended March 31, 2013

May 13 13

Pharmesis International Ltd. reported un-audited consolidated earnings results for the first quarter ended March 31, 2013. For the quarter, the company reported revenue of RMB 15,168,000 compared to RMB 12,418,000, loss from operation of RMB 1,146,000 compared to RMB 5,637,000, loss before tax of RMB 1,124,000 compared to RMB 5,447,000 and loss attributable to equity holders of the company of RMB 1,005,000 or 0.50 per diluted share compared to RMB 4,446,000 or 2.22 per diluted share for the last year. Net cash flows from operating activities were RMB 1,627,000 compared to RMB 4,077,000 and acquisition of property, plant and equipment and construction in progress of RMB 110,000 compared to RMB 16,000 for the last year.

Pharmesis International Ltd. to Report Q1, 2013 Results on May 13, 2013

May 8 13

Pharmesis International Ltd. announced that they will report Q1, 2013 results on May 13, 2013

Pharmesis International Ltd., Annual General Meeting, Apr 26, 2013

Apr 10 13

Pharmesis International Ltd., Annual General Meeting, Apr 26, 2013., at 14:30 Singapore Standard Time. Location: No. 5 Kallang Sector, #03-02. Agenda: To receive and adopt the Directors' Report and the Audited Financial Statements of the company for the financial year ended 31 December 2012 together with the Auditors' Report thereon; to re-elect the Directors retiring pursuant to Article 91 of the company's Articles of Association; to approve the payment of Directors' fees; to re-appoint Ernst & Young LLP as the Company's Auditors and to authorise the Directors to fix their remuneration; to transact any other business which may properly be transacted at an Annual General Meeting; to authorise authority to allot and issue shares under the Pharmesis Employee Share Option Scheme; and to authorise authority to allot and issue shares.